Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
Saved in:
| Title: | Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. |
|---|---|
| Authors: | Maaske J; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Sproule S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Falsey AR; University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.; Rochester Regional Health, Rochester, NY, United States., Sobieszczyk ME; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian Columbia University Irving Medical Center, New York, NY, United States., Luetkemeyer AF; Zuckerberg San Francisco General, University of California, San Francisco, San Francisco, CA, United States., Paulsen GC; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.; Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States., Riddler SA; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States., Robb ML; Walter Reed Army Institute of Research, Silver Spring, MD, United States., Rolle CP; Orlando Immunology Center, Orlando, FL, United States., Sha BE; Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States., Tong T; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Ahani B; Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Aksyuk AA; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Bansal H; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Egan T; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Jepson B; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Padilla M; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Patel N; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Shoemaker K; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Stanley AM; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Swanson PA; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Wilkins D; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Villafana T; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Green JA; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Kelly EJ; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2023 Jan 13; Vol. 13, pp. 1062067. Date of Electronic Publication: 2023 Jan 13 (Print Publication: 2022). |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
